Lv3
240 积分 2023-04-18 加入
Cancer burden and control in China: landscape, trends and challenges
12小时前
已完结
The promise of bispecific antibodies: Clinical applications and challenges
4天前
已完结
Immune-checkpoint inhibitors: long-term implications of toxicity
6天前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
6天前
已完结
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
6天前
已完结
PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
11天前
已完结
Linking tumour angiogenesis and tumour immunity
11天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
18天前
已完结
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?
20天前
已完结
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges
23天前
已完结
皖公网安备34019202002308
